UA48262C2 - <font face="Symbol">b</font>-СУЛЬФОНІЛ ГІДРОКСАМОВІ КИСЛОТИ ЯК ІНГІБІТОРИ МАТРИЧНИХ МЕТАЛОПРОТЕЇНАЗ, ПРОМІЖНА СПОЛУКА ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ - Google Patents

<font face="Symbol">b</font>-СУЛЬФОНІЛ ГІДРОКСАМОВІ КИСЛОТИ ЯК ІНГІБІТОРИ МАТРИЧНИХ МЕТАЛОПРОТЕЇНАЗ, ПРОМІЖНА СПОЛУКА ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ Download PDF

Info

Publication number
UA48262C2
UA48262C2 UA99042348A UA99042348A UA48262C2 UA 48262 C2 UA48262 C2 UA 48262C2 UA 99042348 A UA99042348 A UA 99042348A UA 99042348 A UA99042348 A UA 99042348A UA 48262 C2 UA48262 C2 UA 48262C2
Authority
UA
Ukraine
Prior art keywords
methyl
hydroxy
propionamide
methoxybenzenesulfonyl
substituted
Prior art date
Application number
UA99042348A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Марта А. Варпехоскі
Данальд Е. Харпер
Original Assignee
Фармація Енд Апджон Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармація Енд Апджон Компані filed Critical Фармація Енд Апджон Компані
Publication of UA48262C2 publication Critical patent/UA48262C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
UA99042348A 1996-09-27 1997-09-19 <font face="Symbol">b</font>-СУЛЬФОНІЛ ГІДРОКСАМОВІ КИСЛОТИ ЯК ІНГІБІТОРИ МАТРИЧНИХ МЕТАЛОПРОТЕЇНАЗ, ПРОМІЖНА СПОЛУКА ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ UA48262C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2684896P 1996-09-27 1996-09-27
PCT/US1997/016348 WO1998013340A1 (en) 1996-09-27 1997-09-19 β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS

Publications (1)

Publication Number Publication Date
UA48262C2 true UA48262C2 (uk) 2002-08-15

Family

ID=21834136

Family Applications (1)

Application Number Title Priority Date Filing Date
UA99042348A UA48262C2 (uk) 1996-09-27 1997-09-19 <font face="Symbol">b</font>-СУЛЬФОНІЛ ГІДРОКСАМОВІ КИСЛОТИ ЯК ІНГІБІТОРИ МАТРИЧНИХ МЕТАЛОПРОТЕЇНАЗ, ПРОМІЖНА СПОЛУКА ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ

Country Status (21)

Country Link
US (2) US5847153A (enExample)
EP (1) EP0929519B1 (enExample)
JP (1) JP2001516338A (enExample)
KR (1) KR20000048639A (enExample)
CN (1) CN1158254C (enExample)
AT (1) ATE289590T1 (enExample)
AU (1) AU726799B2 (enExample)
BR (1) BR9712134A (enExample)
CA (1) CA2266368A1 (enExample)
CZ (1) CZ92399A3 (enExample)
DE (1) DE69732571T2 (enExample)
EA (1) EA001460B1 (enExample)
ES (1) ES2236829T3 (enExample)
HU (1) HUP0000145A3 (enExample)
ID (1) ID21897A (enExample)
IL (1) IL128900A0 (enExample)
NO (1) NO312893B1 (enExample)
NZ (1) NZ334729A (enExample)
PL (1) PL332509A1 (enExample)
UA (1) UA48262C2 (enExample)
WO (1) WO1998013340A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968182B1 (en) * 1996-08-07 2004-05-06 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
KR20000048639A (ko) * 1996-09-27 2000-07-25 로렌스 티. 마이젠헬더 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산
DE69829648T2 (de) 1997-01-22 2009-12-10 Aventis Pharmaceuticals Inc. Substituierte β-Thiocarbonsäure
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
ES2209122T3 (es) * 1997-03-04 2004-06-16 Pharmacia Corporation Compuestos de acido sulfonil alfa-hidroxi hidroxamico aromatico.
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6063786A (en) * 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
HUP0100812A3 (en) * 1997-11-21 2002-11-28 Upjohn Co Alpha-hydroxy, -amino and -fluoro derivatives of betha-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors
IL137146A0 (en) * 1998-01-30 2001-07-24 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
ATE402142T1 (de) 1998-06-18 2008-08-15 Hoffmann La Roche Verfahren für arylalkylsulfid
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) * 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
JP2009519349A (ja) 2005-12-15 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
JP5448164B2 (ja) 2006-07-28 2014-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
US7928123B2 (en) * 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2009061652A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2010005782A1 (en) 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
AP2011005674A0 (en) 2008-09-25 2011-04-30 Boehringer Ingelheim Int Sulfonyl compounds which selectively modulate the CB2 receptor.
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8383615B2 (en) 2009-06-16 2013-02-26 Boehringer Ingelheim International Gmbh Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
US8383651B2 (en) 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
EP2595959B1 (en) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB689608A (en) * 1950-04-13 1953-04-01 Basf Ag Improvements in the production of gamma-sulphonyl carboxylic acids
US2659752A (en) * 1951-08-09 1953-11-17 Goodrich Co B F Method for preparing beta-(arylsulfonyl) carboxylic acids and salts thereof
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
JP3348725B2 (ja) * 1992-04-07 2002-11-20 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤
DE4233100A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Sulfonylmethylpropionsäuren sowie Zwischenprodukte
DE4233099A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Thiomethylpropionsäuren
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
AU1529897A (en) * 1996-01-02 1997-07-28 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
KR20000048639A (ko) * 1996-09-27 2000-07-25 로렌스 티. 마이젠헬더 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds

Also Published As

Publication number Publication date
ID21897A (id) 1999-08-05
AU4645997A (en) 1998-04-17
EP0929519A1 (en) 1999-07-21
HK1022468A1 (en) 2000-08-11
NO991494L (no) 1999-05-26
HUP0000145A3 (en) 2001-12-28
EA001460B1 (ru) 2001-04-23
US5847153A (en) 1998-12-08
ATE289590T1 (de) 2005-03-15
NZ334729A (en) 2001-01-26
PL332509A1 (en) 1999-09-13
CZ92399A3 (cs) 1999-07-14
EA199900332A1 (ru) 1999-12-29
AU726799B2 (en) 2000-11-23
WO1998013340A1 (en) 1998-04-02
CA2266368A1 (en) 1998-04-02
KR20000048639A (ko) 2000-07-25
IL128900A0 (en) 2000-01-31
JP2001516338A (ja) 2001-09-25
CN1230177A (zh) 1999-09-29
HUP0000145A2 (en) 2000-07-28
DE69732571T2 (de) 2006-01-12
EP0929519B1 (en) 2005-02-23
ES2236829T3 (es) 2005-07-16
BR9712134A (pt) 1999-08-31
US6235928B1 (en) 2001-05-22
CN1158254C (zh) 2004-07-21
NO312893B1 (no) 2002-07-15
DE69732571D1 (de) 2005-03-31
NO991494D0 (no) 1999-03-26

Similar Documents

Publication Publication Date Title
UA48262C2 (uk) &lt;font face=&#34;Symbol&#34;&gt;b&lt;/font&gt;-СУЛЬФОНІЛ ГІДРОКСАМОВІ КИСЛОТИ ЯК ІНГІБІТОРИ МАТРИЧНИХ МЕТАЛОПРОТЕЇНАЗ, ПРОМІЖНА СПОЛУКА ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
EP1037868B1 (en) $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
DE69419473T2 (de) Peptidylderivate als inhibitoren von metalloproteinase
AU776171C (en) Alpha-amino-beta-sulfonyl hydroxamic acid compounds
JP2003519100A (ja) ベータ二置換メタロプロテアーゼ阻害剤
MXPA99002807A (en) &amp;bgr;-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
US20040142975A1 (en) Beta disubstituted metalloprotease inhibitors
EP0979816A1 (fr) Nouveaux dérivés d&#39;acide hydroxamique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CZ20001886A3 (cs) Alfa-hydroxy, alfa-amino a alfa-haloderiváty Bsulfonylhydroxamových kyselin jako inhibitory matricových metaloproteináz
MXPA00004937A (en) &amp;agr;-HYDROXY, -AMINO, AND HALO DERIVATIVES OF&amp;bgr;-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
HK1025314A (en) New hydroxamic acid compounds, a process for their preparation and pharmaceutical compositions containing them
CA2274889A1 (en) Bis-sulfonomides hydroxamic acids as mmp inhibitors